JPMorgan Chase & Co. Increases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

JPMorgan Chase & Co. grew its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 53.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 243,628 shares of the biotechnology company’s stock after buying an additional 85,082 shares during the period. JPMorgan Chase & Co. owned approximately 1.15% of Enanta Pharmaceuticals worth $2,524,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. US Bancorp DE lifted its holdings in shares of Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 4,243 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Enanta Pharmaceuticals during the third quarter valued at about $122,000. Quest Partners LLC lifted its stake in Enanta Pharmaceuticals by 65.0% during the third quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 7,535 shares during the last quarter. Valence8 US LP purchased a new position in shares of Enanta Pharmaceuticals in the 3rd quarter worth about $207,000. Finally, Barclays PLC increased its position in shares of Enanta Pharmaceuticals by 294.2% during the 3rd quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock valued at $285,000 after purchasing an additional 20,478 shares during the last quarter. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA stock opened at $5.25 on Tuesday. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $17.80. The stock has a 50 day moving average price of $7.12 and a two-hundred day moving average price of $10.65. The company has a market capitalization of $111.27 million, a P/E ratio of -0.96 and a beta of 0.56.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The business had revenue of $14.60 million during the quarter, compared to the consensus estimate of $17.99 million. During the same period in the previous year, the business earned ($1.33) earnings per share. The firm’s revenue for the quarter was down 22.8% compared to the same quarter last year. As a group, equities analysts predict that Enanta Pharmaceuticals, Inc. will post -4.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ENTA. Robert W. Baird cut their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. JMP Securities restated a “market outperform” rating and issued a $21.00 price objective (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Finally, HC Wainwright reduced their target price on shares of Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, December 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.25.

Insider Activity at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the transaction, the chief executive officer now owns 801,638 shares in the company, valued at approximately $6,461,202.28. This represents a 0.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 13.64% of the stock is currently owned by company insiders.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.